News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
731,027 Results
Type
Article (41373)
Company Profile (310)
Press Release (689334)
Multimedia
Podcasts (82)
Webinars (17)
Section
Business (207072)
Career Advice (2039)
Deals (35857)
Drug Delivery (114)
Drug Development (82469)
Employer Resources (175)
FDA (16467)
Job Trends (15086)
News (350307)
Policy (32941)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2581)
Accelerated approval (37)
Adcomms (24)
Allergies (150)
Alliances (50229)
ALS (177)
Alzheimer's disease (1688)
Antibody-drug conjugate (ADC) (326)
Approvals (16755)
Artificial intelligence (542)
Autoimmune disease (165)
Automation (45)
Bankruptcy (361)
Best Places to Work (11737)
BIOSECURE Act (20)
Biosimilars (198)
Biotechnology (205)
Bladder cancer (165)
Brain cancer (59)
Breast cancer (654)
Cancer (4973)
Cardiovascular disease (422)
Career advice (1722)
Career pathing (37)
CAR-T (287)
CDC (48)
Celiac Disease (2)
Cell therapy (763)
Cervical cancer (37)
Clinical research (70625)
Collaboration (1778)
Company closure (4)
Compensation (1195)
Complete response letters (58)
COVID-19 (2726)
CRISPR (95)
C-suite (895)
Cystic fibrosis (145)
Data (6451)
Decentralized trials (2)
Denatured (25)
Depression (139)
Diabetes (510)
Diagnostics (6751)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (262)
Drug pricing (187)
Drug shortages (28)
Duchenne muscular dystrophy (239)
Earnings (91412)
Editorial (59)
Employer branding (22)
Employer resources (154)
Events (119871)
Executive appointments (1006)
FDA (19676)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1509)
Gene editing (203)
Generative AI (44)
Gene therapy (614)
GLP-1 (989)
Government (4688)
Grass and pollen (7)
Guidances (385)
Healthcare (18938)
HIV (69)
Huntington's disease (47)
IgA nephropathy (84)
Immunology and inflammation (254)
Immuno-oncology (65)
Indications (128)
Infectious disease (3010)
Inflammatory bowel disease (196)
Inflation Reduction Act (14)
Influenza (122)
Intellectual property (259)
Interviews (320)
IPO (16832)
IRA (50)
Job creations (3690)
Job search strategy (1437)
JPM (57)
Kidney cancer (18)
Labor market (87)
Layoffs (551)
Leadership (33)
Legal (7978)
Liver cancer (92)
Longevity (18)
Lung cancer (670)
Lymphoma (386)
Machine learning (45)
Management (59)
Manufacturing (829)
MASH (169)
Medical device (13803)
Medtech (13863)
Mergers & acquisitions (20122)
Metabolic disorders (1298)
mRNA (158)
Multiple sclerosis (169)
NASH (16)
Neurodegenerative disease (333)
Neuropsychiatric disorders (89)
Neuroscience (2971)
Neurotech (1)
NextGen: Class of 2026 (6546)
Non-profit (4530)
Now hiring (69)
Obesity (609)
Opinion (266)
Ovarian cancer (168)
Pain (207)
Pancreatic cancer (237)
Parkinson's disease (292)
Partnered (33)
Patents (517)
Patient recruitment (526)
Peanut (59)
People (59682)
Pharmaceutical (73)
Pharmacy benefit managers (30)
Phase 1 (22046)
Phase 2 (31130)
Phase 3 (23075)
Pipeline (5784)
Policy (293)
Postmarket research (2570)
Preclinical (9352)
Press Release (64)
Prostate cancer (253)
Psychedelics (48)
Radiopharmaceuticals (298)
Rare diseases (882)
Real estate (6045)
Recruiting (71)
Regulatory (24806)
Reports (53)
Research institute (2408)
Resumes & cover letters (353)
Rett syndrome (29)
RNA editing (16)
RSV (81)
Schizophrenia (152)
Series A (249)
Series B (193)
Service/supplier (11)
Sickle cell disease (101)
Special edition (22)
Spinal muscular atrophy (158)
Sponsored (42)
Startups (3663)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (84)
The Weekly (55)
Vaccines (1024)
Venture capital (91)
Weight loss (390)
Women's health (98)
Worklife (19)
Date
Today (190)
Last 7 days (882)
Last 30 days (2923)
Last 365 days (30226)
2026 (4879)
2025 (30429)
2024 (35560)
2023 (40472)
2022 (51634)
2021 (56245)
2020 (54471)
2019 (46898)
2018 (35314)
2017 (32506)
2016 (31947)
2015 (38018)
2014 (31843)
2013 (26766)
2012 (28940)
2011 (29608)
2010 (27666)
Location
Africa (746)
Alabama (91)
Alaska (7)
Arizona (317)
Arkansas (14)
Asia (40250)
Australia (6536)
California (11650)
Canada (3360)
China (1154)
Colorado (492)
Connecticut (492)
Delaware (343)
Europe (87569)
Florida (1768)
Georgia (370)
Hawaii (3)
Idaho (61)
Illinois (888)
India (71)
Indiana (537)
Iowa (22)
Japan (444)
Kansas (127)
Kentucky (42)
Louisiana (27)
Maine (72)
Maryland (1423)
Massachusetts (8388)
Michigan (335)
Minnesota (638)
Mississippi (6)
Missouri (129)
Montana (32)
Nebraska (29)
Nevada (125)
New Hampshire (80)
New Jersey (3104)
New Mexico (29)
New York (3081)
North Carolina (1543)
North Dakota (8)
Northern California (5720)
Ohio (346)
Oklahoma (21)
Oregon (42)
Pennsylvania (2346)
Puerto Rico (25)
Rhode Island (49)
South America (1121)
South Carolina (68)
South Dakota (1)
Southern California (4539)
Tennessee (179)
Texas (1795)
United States (41408)
Utah (350)
Vermont (1)
Virginia (275)
Washington D.C. (81)
Washington State (954)
West Virginia (4)
Wisconsin (114)
Wyoming (2)
731,027 Results for "provectus biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
September 30, 2025
·
3 min read
Press Releases
Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders
June 9, 2025
·
3 min read
Business
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
Provectus Biopharmaceuticals, Inc. today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.
April 18, 2024
·
4 min read
Press Releases
Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy
October 10, 2025
·
5 min read
BioMidwest
Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders
Provectus Biopharmaceuticals, Inc. announced that its 2024 annual stockholder meeting, including meeting activities and a company update, will be accessible by Zoom Webinar.
June 13, 2024
·
5 min read
Business
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
Provectus Biopharmaceuticals, Inc. today announced additions to its executive leadership team, reflecting Provectus’s dedication to enhancing shareholder value.
April 16, 2024
·
6 min read
Press Releases
Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer
June 26, 2025
·
4 min read
BioMidwest
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
Provectus Biopharmaceuticals, Inc. announced that it has engaged IR Labs, Inc. to develop a comprehensive investor relations and corporate communications program for the Company.
February 14, 2024
·
3 min read
Press Releases
Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs
January 15, 2025
·
5 min read
Business
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
Provectus Biopharmaceuticals, Inc. announced that it will host a conference call starting at 3 p.m. EST on Thursday, February 22, 2024, to provide Company updates.
February 15, 2024
·
3 min read
1 of 73,103
Next
